Keryx announces results from ferric citrate phase 3 long-term safety extension study

(Edelman Public Relations) Keryx Biopharmaceuticals, Inc. today announced results from a 48-week Open Label Extension (OLE) safety study in which Ferric Citrate demonstrated long-term safety and efficacy in dialysis-dependent chronic kidney disease patients with elevated serum phosphorus levels, or hyperphosphatemia. The OLE findings were presented as a late-breaking poster (Abstract #SA-PO1102) at the 2014 American Society of Nephrology's Kidney Week meeting in Philadelphia, Pa.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news